BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Quarterly Reports

Q3 2019 Report

Tuesday, 19 NovemberArctic Securities, Haakon VIIs gate 5, Oslo

The webcast will be streamed LIVE and the recording will be available after LIVE session is finished.

Link to live webcast

Corporate Presentation

H.C. Wainwright 21st Annual Global Life Sciences Conference

Sept 10th, 2019

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO PRESENTS PRELIMINARY CLINICAL DATA FROM PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY AML PATIENTS AT ASH 2019

BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER 2019

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

More News

Scientific Presentations

ASH 2019, Sonja Loges et al

9 December 2019Orlando, USA

Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.

Read More

Annual Report 2018

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

Third quarter 2019 results presentation and webcast

Meet us in Maryland during SITC 2019!

BerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference 2019, April 7-9

More Events